Skip to main content
. 2010 Sep 1;5(9):e12515. doi: 10.1371/journal.pone.0012515

Figure 3. Oral treatment of Lodamin reduces CNV progression.

Figure 3

(A) CNV lesion size of Lodamin-treated mice compared to controls. A dose of 15 mg/kg/day was administered for 7 or 14 days and a dose of 30 mg/kg/day was administered for 7 days. CNV lesions in choroidal flat mounts were evaluated after staining of blood vessels using isolectin-IB4 conjugated with Alexa Fluor 488. Data are presented as percent of blood vessel area in choroidal flat mounts (pixels) of treatment per controls. Data are expressed as mean ± SEM, (U-test, * P<0.05, ** P<0.005, n = 10). (B) Representative images of CNV lesions stained with a lectin-FITC in flat mount of mouse choroids. Bar = 20 µm. (C) H&E stained histological side sections of CNV site in Lodamin treated or untreated mice. Substantial differences in fibrous tissues thickness and choroidal vessel invasion to CNV site are detected, Bars = 50 µm (D) FACS analysis of single-cell suspension originated from retinas after 3 and 7 days of oral Lodamin treatment. Quantification of macrophage infiltration in mouse retinas originated from Lodamin treated (30 mg/kg, daily, oral) or mice which were treated with equivalent dose of vehicle. Macrophage population was detected as a double positive CD45+ and F4/80+ staining.